Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: January 31, 2023

Details for Patent: 8,946,250

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,946,250 protect, and when does it expire?

Patent 8,946,250 protects BRAFTOVI and is included in one NDA.

This patent has twenty-one patent family members in nineteen countries.

Summary for Patent: 8,946,250
Title:3,4-diarylpyrazoles as protein kinase inhibitors
Abstract: 3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. ##STR00001##
Inventor(s): Pulici; Maurizio (Caponago, IT), Zuccotto; Fabio (Milan, IT), Traquandi; Gabriella (Milan, IT), Biondaro; Sonia (Ronca, IT), Trifiro'; Paolo (Genoa, IT), Badari; Alessandra (Vedano al Lambro, IT), Nuvoloni; Stefano (Genoa, IT), Cervi; Giovanni (Como, IT), Marchionni; Chiara (Milan, IT), Modugno; Michele (Cernusco sul Naviglio, IT)
Assignee: Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT)
Application Number:13/970,854
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,946,250

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-001 Jun 27, 2018 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,946,250

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08161076Jul 24, 2008

International Family Members for US Patent 8,946,250

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 557015 See Plans and Pricing
Australia 2009273197 See Plans and Pricing
Brazil PI0916356 See Plans and Pricing
Canada 2731146 See Plans and Pricing
Chile 2011000124 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.